Recent Advances in Clinical Trials in Multiple System Atrophy
Current Neurology and Neuroscience Reports · 2024
DOI: 10.1007/s11910-024-01335-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Neurology and Neuroscience Reports, 2024. Verfasst von David Bendetowicz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Bordeaux, CNRS, IMN, UMR5293, Bordeaux, France. david.bendetowicz@u-bordeaux.fr. Hauptthemen laut MEDLINE: Multiple System Atrophy, Parkinsonian Disorders. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 126 Literaturangaben.
Abstract (Originalsprache)
PURPOSE OF REVIEW: This review summarizes previous and ongoing neuroprotection trials in multiple system atrophy (MSA), a rare and fatal neurodegenerative disease characterized by parkinsonism, cerebellar, and autonomic dysfunction. It also describes the preclinical therapeutic pipeline and provides some considerations relevant to successfully conducting clinical trials in MSA, i.e., diagnosis, endpoints, and trial design. RECENT FINDINGS: Over 30 compounds have been tested in clinical trials in MSA. While this illustrates a strong treatment pipeline, only two have reached their primary endpoint. Ongoing clinical trials primarily focus on targeting α-synuclein, the neuropathological hallmark of MSA being α-synuclein-bearing glial cytoplasmic inclusions. The mostly negative trial outcomes highlight the importance of better understanding underlying disease mechanisms and improving preclinical models. Together with efforts to refine clinical measurement tools, innovative statistical methods, and developments in biomarker research, this will enhance the design of future neuroprotection trials in MSA and the likelihood of positive outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Bordeaux, CNRS, IMN, UMR5293, Bordeaux, France. david.bendetowicz@u-bordeaux.fr.
- CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, CRMR AMS, NS-Park/FCRIN Network, Bordeaux, France. david.bendetowicz@u-bordeaux.fr.
- MSA French Reference Center, Univ. Hospital Toulouse, Toulouse, France.
- Univ. Toulouse, CIC-1436, Departments of Clinical Pharmacology and Neurosciences, NeuroToul COEN Center, NS-Park/FCRIN Network, Toulouse University Hospital, Inserm, U1048/1214, Toulouse, France.
- Univ. Bordeaux, INSERM, BPH, U1219, IPSED, Bordeaux, France.
- Université de Poitiers, Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM UMR-S 1084, Poitiers, France.
Zitieren
APA
Bendetowicz, D., Fabbri, M., Sirna, F., Fernagut, P. O., Foubert-Samier, A., Saulnier, T., Le Traon, A. P., Proust-Lima, C., Rascol, O., & Meissner, W. G. (2024). Recent Advances in Clinical Trials in Multiple System Atrophy. Current Neurology and Neuroscience Reports. https://doi.org/10.1007/s11910-024-01335-0
Vancouver
Bendetowicz D, Fabbri M, Sirna F, Fernagut PO, Foubert-Samier A, Saulnier T, et al. Recent Advances in Clinical Trials in Multiple System Atrophy. Current Neurology and Neuroscience Reports. 2024. doi:10.1007/s11910-024-01335-0
BibTeX
@article{Bendetowicz2024,
author = {Bendetowicz, David and Fabbri, Margherita and Sirna, Federico and Fernagut, Pierre-Olivier and Foubert-Samier, Alexandra and Saulnier, Tiphaine and Le Traon, Anne Pavy and Proust-Lima, Cécile and Rascol, Olivier and Meissner, Wassilios G},
title = {Recent Advances in Clinical Trials in Multiple System Atrophy},
journal = {Current Neurology and Neuroscience Reports},
year = {2024},
doi = {10.1007/s11910-024-01335-0}
}
EUVIMED